



# UNICHEM LABORATORIES LTD.

Regd. Office: Unichem Bhavan, Prabhat Estate, Off. S. V. Road,  
Jogeshwari (West), Mumbai – 400 102. Tel: 66888333. Fax: 26794089

## Statement of Standalone Unaudited Results for the Quarter ended & Nine Months ended 31st December, 2013.

PART I							(Rs. in Lacs)
Particulars	Three months ended 31 <sup>st</sup> Dec' 13 (Unaudited)	Three months ended 30 <sup>th</sup> Sep' 13 (Unaudited)	Three months ended 31 <sup>st</sup> Dec' 12 (Unaudited)	Nine Months ended 31 <sup>st</sup> Dec' 13 (Unaudited)	Nine Months ended 31 <sup>st</sup> Dec' 12 (Unaudited)	Accounting Year ended 31 <sup>st</sup> Mar' 13 (Audited)	
<b>INCOME FROM OPERATIONS</b>							
1 a) Net Sales/Income from operations (Net of excise duty)	26,303.88	26,618.75	23,116.33	79,143.09	75,562.85	99,685.95	
b) Other Operating Income	187.11	338.37	141.58	862.90	605.84	835.74	
<b>TOTAL INCOME FROM OPERATIONS (NET)</b>	<b>26,490.99</b>	<b>26,957.12</b>	<b>23,257.91</b>	<b>80,005.99</b>	<b>76,168.69</b>	<b>100,521.69</b>	
<b>EXPENSES</b>							
a) Cost of Material Consumed	6,879.38	6,661.56	6,223.78	20,093.32	19,551.19	26,127.92	
b) Purchases of stock-in-trade	3,527.70	3,321.03	2,436.80	10,359.00	8,621.31	10,784.43	
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,300.42)	(562.27)	(322.20)	(2,329.81)	137.99	1,007.31	
d) Employee benefits' expense	3,996.70	4,144.91	3,672.47	12,273.42	10,644.67	14,114.73	
e) Depreciation and amortisation expense	1,010.76	1,097.97	854.02	3,176.91	2,502.50	3,481.65	
f) Other expenses	8,577.27	8,370.73	7,211.84	24,692.81	22,894.97	29,919.56	
<b>TOTAL EXPENSES</b>	<b>22,691.39</b>	<b>23,033.93</b>	<b>20,076.71</b>	<b>68,265.65</b>	<b>64,352.63</b>	<b>85,435.60</b>	
<b>Profit/(Loss) from operations before other income, finance costs and exceptional items (1-2)</b>	<b>3,799.60</b>	<b>3,923.19</b>	<b>3,181.20</b>	<b>11,740.34</b>	<b>11,816.06</b>	<b>15,086.09</b>	
4 Other Income	328.95	770.42	464.85	1,860.36	1,158.65	1,406.70	
<b>Profit/(Loss) from ordinary activities before finance costs and exceptional items (3+4)</b>	<b>4,128.55</b>	<b>4,693.61</b>	<b>3,646.05</b>	<b>13,600.70</b>	<b>12,974.71</b>	<b>16,492.79</b>	
6 Finance costs	58.04	64.88	54.35	184.59	206.50	248.16	
<b>Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6)</b>	<b>4,070.51</b>	<b>4,628.73</b>	<b>3,591.70</b>	<b>13,416.11</b>	<b>12,768.21</b>	<b>16,244.63</b>	
8 Exceptional Items (refer note 4 below)	4,916.55	-	-	4,916.55	-	-	
<b>Profit/(Loss) from ordinary activities before tax (7+8)</b>	<b>8,987.06</b>	<b>4,628.73</b>	<b>3,591.70</b>	<b>18,332.66</b>	<b>12,768.21</b>	<b>16,244.63</b>	
10 Tax Expenses	1,569.06	1,008.00	557.00	3,684.06	2,912.00	3,285.03	
<b>Net profit from ordinary activities after tax including exceptional items (9 - 10)</b>	<b>7,418.00</b>	<b>3,620.73</b>	<b>3,034.70</b>	<b>14,648.60</b>	<b>9,856.21</b>	<b>12,959.60</b>	
<b>Net profit for the period excluding exceptional items</b>	<b>3,214.51</b>	<b>3,620.73</b>	<b>3,034.70</b>	<b>10,445.11</b>	<b>9,856.21</b>	<b>12,959.60</b>	
13 Paid up Equity Share Capital ( Face Value Rs. 2 per share)	1,811.94	1,811.73	1,808.96	1,811.94	1,808.96	1,809.13	
14 Reserves & Surplus excluding Revaluation Reserve as per balance sheet of previous accounting year.						79,486.15	
15 Earning Per Share ( Face Value of Rs. 2/ each) including exceptional items							
a) Basic - Rs.	8.19	4.00	3.36	16.18	10.90	14.33	
b) Diluted - Rs.	8.18	3.99	3.35	16.15	10.86	14.29	
<b>16 Earning Per Share ( Face Value of Rs. 2/ each) excluding exceptional items</b>							
a) Basic - Rs.	3.55	4.00	3.36	11.54	10.90	14.33	
b) Diluted - Rs.	3.54	3.99	3.35	11.51	10.86	14.29	

PART II						
A. PARTICULARS OF SHAREHOLDING						
1 Public Shareholding						
Number of Shares	45,086,676	45,076,051	45,651,886	45,086,676	45,651,886	45,220,198
Percentage of Shareholding	49.77%	49.76%	50.47%	49.77%	50.47%	49.99%
2 Promoters and Promoters group shareholding						
a) Pledged /Encumbered						
- Number of Shares	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of shares ( as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of shares ( as a % of the total share capital of the company )	Nil	Nil	Nil	Nil	Nil	Nil
b) Non- encumbered						
- Number of Shares	45,510,550	45,510,550	44,796,240	45,510,550	44,796,240	45,236,240
- Percentage of shares ( as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of shares ( as a % of the total share capital of the company )	50.23%	50.24%	49.53%	50.23%	49.53%	50.01%

Particulars	Quarter Ended 31.12.2013
<b>B. INVESTOR COMPLAINTS</b>	
Pending at the beginning of the quarter	NIL
Received during the quarter	13
Disposed of during the quarter	13
Remaining unresolved at the end of the quarter	NIL

1 The above results have been subjected to Limited Review by the Statutory Auditors, reviewed by the Audit Committee and taken on record by the Board of Directors of the Company in its meeting held on 18th January, 2014.

2 Segment Reporting: Primary Segment  
The Company has only one segment i.e. 'Pharmaceuticals'.  
**Secondary Segment (By Geographical Segment)**

Net Sales and Operating Income	Three months ended 31 <sup>st</sup> Dec' 13 (Unaudited)	Three months ended 30 <sup>th</sup> Sep' 13 (Unaudited)	Three months ended 31 <sup>st</sup> Dec' 12 (Unaudited)	Nine Months ended 31 <sup>st</sup> Dec' 13 (Unaudited)	Nine Months ended 31 <sup>st</sup> Dec' 12 (Unaudited)	Accounting Year ended 31 <sup>st</sup> Mar' 13 (Audited)
Within India	17,602.56	18,090.25	15,696.44	53,796.57	51,063.98	65,760.55
Outside India	8,888.43	8,866.87	7,561.47	26,209.42	25,104.71	34,761.14
<b>Total</b>	<b>26,490.99</b>	<b>26,957.12</b>	<b>23,257.91</b>	<b>80,005.99</b>	<b>76,168.69</b>	<b>100,521.69</b>

In view of the interwoven / intermix nature of the business and manufacturing facility, other segmental information is not ascertainable.

3 Other Income includes exchange gain as under:							(Rs. in Lacs)
Exchange Difference	Three months ended 31 <sup>st</sup> Dec' 13 (Unaudited)	Three months ended 30 <sup>th</sup> Sep' 13 (Unaudited)	Three months ended 31 <sup>st</sup> Dec' 12 (Unaudited)	Nine Months ended 31 <sup>st</sup> Dec' 13 (Unaudited)	Nine Months ended 31 <sup>st</sup> Dec' 12 (Unaudited)	Accounting Year ended 31 <sup>st</sup> Mar' 13 (Audited)	
<b>Exchange gain included in Other Income</b>	<b>38.27</b>	<b>408.01</b>	<b>292.58</b>	<b>968.46</b>	<b>641.72</b>	<b>574.62</b>	

4 Exceptional Items represents profits on sale of Company's manufacturing unit at SEZ, Indore and amortisation of Intangible assets due to change in their estimated useful life.

5 The Board declared an interim dividend of Rs.4 Per share(200%) ( Face value Rs. 2/- per share each). ( Previous year: final Dividend Rs. 4.50/- ( 225%) per share on Face Value share of Rs. 2/- each).

6 Previous years figures have been regrouped / reclassified wherever necessary.

Place : Mumbai  
Date : 18<sup>th</sup> January, 2014

By Order of the Board  
For **Unichem Laboratories Ltd.**  
Sd/-  
**Dr. Prakash A. Mody**  
Chairman & Managing Director